VBI Vaccines Inc. (VBIV) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 8, 2022 8:00 AM EDTPreHevbrio [Hepatitis B Vaccine (Recombinant)] launched in the U.S. at the end of Q1 2022 advancing through commercial stage gates required to enable broad access to the 3-antigen adult hepatitis B (HBV) vaccine FDA Orphan Drug Designation received for VBI-1901 for treatment of glioblastoma (GBM) in June 2022 Two new clinical studies in GBM patients expected to start before the end of 2022 In partnership with the Government of Canada, new clinical study assessing pan-coronavirus vaccine candidate expected to start in Q3 2022 Initial Phase 2 human proof of concept combination study data from VBI-2601 + siRNA in... More
